FDA approved alectinib for adjuvant ALK-positive NSCLC on April 18, 2024Nov 6Regulatory decisionalectinibRoche
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
Sign inSign in